Clinical Trial Detail

NCT ID NCT03332017
Title A Study Comparing Obinutuzumab and BGB-3111 Versus Obinutuzumab Alone in Treating R/R Follicular Lymphoma
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors BeiGene
Indications

follicular lymphoma

Therapies

Obinutuzumab + Zanubrutinib

Obinutuzumab

Age Groups: adult senior

No variant requirements are available.